BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11373937)

  • 1. [Follow-up of differentiated thyroid cancer patients using rhTSH--preliminary results].
    Petrich T; Börner AR; Weckesser E; Soudah B; Otto D; Widjaja A; Hofmann M; Kreipe HH; Knapp WH
    Nuklearmedizin; 2001 Feb; 40(1):7-14. PubMed ID: 11373937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
    Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
    Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma.
    Petrich T; Börner AR; Otto D; Hofmann M; Knapp WH
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):641-7. PubMed ID: 11976802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma].
    Caresia AP; Castell Conesa J; Obiols Alfonso G; Pifarré Montaner P; Negre Busó M; García Alonso C; Galofré Mora P; Mesa Manteca J
    Rev Esp Med Nucl; 2006; 25(4):236-41. PubMed ID: 16827986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
    Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
    Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
    David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
    Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer.
    Alzahrani AS; AlShaikh O; Tuli M; Al-Sugair A; Alamawi R; Al-Rasheed MM
    Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH.
    Emmanouilidis N; Müller JA; Jäger MD; Kaaden S; Helfritz FA; Güner Z; Kespohl H; Knitsch W; Knapp WH; Klempnauer J; Scheumann GF
    Eur J Endocrinol; 2009 Nov; 161(5):763-9. PubMed ID: 19687168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.
    Altenvoerde G; Lerch H; Kuwert T; Matheja P; Schäfers M; Schober O
    Langenbecks Arch Surg; 1998 Apr; 383(2):160-3. PubMed ID: 9641890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.
    Leboulleux S; Schroeder PR; Busaidy NL; Auperin A; Corone C; Jacene HA; Ewertz ME; Bournaud C; Wahl RL; Sherman SI; Ladenson PW; Schlumberger M
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1310-6. PubMed ID: 19158200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
    Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproducibility of whole-body 131I scan and serum thyrotropin and stimulated thyroglobulin values in patients studied twice after injection of recombinant human thyrotropin.
    Niederkohr RD; McDougall IR
    Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):363-7. PubMed ID: 17021814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2)].
    Dietlein M; Dressler J; Eschner W; Leisner B; Reiners C; Schicha H; ;
    Nuklearmedizin; 2003 Jun; 42(3):123-5. PubMed ID: 12802477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
    Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
    David A; Blotta A; Bondanelli M; Rossi R; Roti E; Braverman LE; Busutti L; degli Uberti EC
    J Nucl Med; 2001 Oct; 42(10):1470-5. PubMed ID: 11585859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.